Omeros Corp. Announces Upcoming Presentations of New Data on OMIDRIA® at the American Society of Cataract & Refractive Surge...
April 13 2018 - 9:10AM
Business Wire
Omeros Corporation (NASDAQ: OMER) today announced that the
results of four studies directed to the benefits of OMIDRIA across
a range of clinical situations in cataract surgery will be
presented at the upcoming American Society of Cataract and
Refractive Surgery (ASCRS) Congress in Washington, D.C., April
13-17, 2018.
The four presentations are scheduled as follows:
Saturday, April 14: 1:41 PM – 1:46 PMWalter E. Washington
Convention Center – Room 143AMiosis Prevention in
Femtosecond-Assisted Cataract Surgery Using a Continuous Infusion
of Phenylephrine and Ketorolac. Walter K, Delwadia N
Monday, April 16: 1:29 PM – 1:34 PMWalter E. Washington
Convention Center – Room 143BEffect of Early Phenylephrine and
Ketorolac Injection 1%/0.3% on Pupil Diameter in Traditional and
Femtosecond-Assisted Cataract Surgery. Gayton J.
Monday, April 16: 2:08 PM – 2:13 PMWalter E. Washington
Convention Center – Room 143BEffect of Phenylephrine and
Ketorolac Injection on Intraoperative Floppy Iris Syndrome.
Silverstein S., Rana V.
Monday, April 16: 2:13 PM – 2:18 PMWalter E. Washington
Convention Center – Room 143BClinical Outcomes of
Phenylephrine/Ketorolac (1%/0.3%) vs. Epinephrine in Cataract
Surgery in a Real-World Setting. Matossian C.
About OMIDRIA®
Omeros’ OMIDRIA® (phenylephrine and ketorolac intraocular
solution) 1% / 0.3% is the first and only FDA-approved product of
its kind and is marketed in the U.S. for use during cataract
surgery or intraocular lens replacement to maintain pupil size by
preventing intraoperative miosis (pupil constriction) and to reduce
postoperative ocular pain. OMIDRIA also is the only
NSAID-containing product FDA-approved for intraocular use. In
post-launch studies across conventional and femtosecond
laser-assisted cataract surgery, OMIDRIA has been shown (1) to be
effective in patients with intraoperative floppy iris syndrome
(IFIS), pseudoexfoliation and other ophthalmic conditions, (2) to
significantly reduce complication rates, use of pupil-expanding
devices, and surgical times, and (3) to significantly improve
uncorrected visual acuity on the first day following cataract
surgery. While OMIDRIA is broadly indicated for use in cataract
surgery, the above outcomes are not in its currently approved
labeling. Surgical time was not an endpoint in the OMIDRIA Phase 3
clinical trials and did not reach statistical significance in post
hoc analysis of the Phase 3 data.
Important Safety Information for OMIDRIA®
Systemic exposure of phenylephrine may cause elevations in blood
pressure. In clinical trials, the most common reported ocular
adverse reactions at two percent or greater are eye irritation,
posterior capsule opacification, increased intraocular pressure,
and anterior chamber inflammation; incidence of adverse events was
similar between placebo-treated and OMIDRIA-treated patients.
OMIDRIA must be added to irrigation solution prior to intraocular
use.
About Omeros Corporation
In addition to Omeros’ commercial drug OMIDRIA, Omeros has
multiple Phase 3 and Phase 2 clinical-stage development programs
focused on: complement-associated thrombotic microangiopathies;
complement-mediated glomerulonephropathies; Huntington’s disease
and cognitive impairment; and addictive and compulsive disorders.
In addition, Omeros has a diverse group of preclinical programs and
a proprietary G protein-coupled receptor (GPCR) platform through
which it controls 54 new GPCR drug targets and corresponding
compounds, a number of which are in preclinical development. The
company also exclusively possesses a novel antibody-generating
platform.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, which are
subject to the “safe harbor” created by those sections for such
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “anticipate,” “believe,” “could,” “estimate,” “expect,”
“goal,” “intend,” “likely,” “look forward to,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “will,” “would” and
similar expressions and variations thereof. Forward-looking
statements are based on management’s beliefs and assumptions and on
information available to management only as of the date of this
press release. Omeros’ actual results could differ materially from
those anticipated in these forward-looking statements for many
reasons, including, without limitation, risks associated with
product commercialization and commercial operations, unproven
preclinical and clinical development activities, regulatory
oversight, intellectual property claims, competitive developments,
litigation, and the risks, uncertainties and other factors
described under the heading “Risk Factors” in the company’s Annual
Report on Form 10-K filed with the Securities and Exchange
Commission on March 1, 2018. Given these risks, uncertainties and
other factors, you should not place undue reliance on these
forward-looking statements, and the company assumes no obligation
to update these forward-looking statements, even if new information
becomes available in the future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180413005154/en/
Cook Williams Communications, Inc.Jennifer Cook Williams,
360-668-3701Investor and Media Relationsjennifer@cwcomm.org
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Apr 2024 to May 2024
Omeros (NASDAQ:OMER)
Historical Stock Chart
From May 2023 to May 2024